ALTIMI Trademark

Trademark Overview


On Sunday, February 17, 2019, a trademark application was filed for ALTIMI with the United States Patent and Trademark Office. The USPTO has given the ALTIMI trademark a serial number of 88304845. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Sunday, September 19, 2021. This trademark is owned by Altimi Biosciences, Inc.. The ALTIMI trademark is filed in the Pharmaceutical Products category with the following description:

House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, p...
altimi

General Information


Serial Number88304845
Word MarkALTIMI
Filing DateSunday, February 17, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateSunday, September 19, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 15, 2020

Trademark Statements


Goods and ServicesHouse mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, March 10, 2019
Primary Code005
First Use Anywhere DateWednesday, July 1, 2020
First Use In Commerce DateWednesday, July 1, 2020

Trademark Owner History


Party NameAltimi Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPalos Park, IL 60464

Party NameAltimi Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPalos Park, IL 60464

Trademark Events


Event DateEvent Description
Monday, September 20, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Sunday, September 19, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Sunday, March 7, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, March 7, 2021NON-FINAL ACTION E-MAILED
Sunday, March 7, 2021SU - NON-FINAL ACTION - WRITTEN
Tuesday, March 2, 2021STATEMENT OF USE PROCESSING COMPLETE
Wednesday, February 10, 2021USE AMENDMENT FILED
Monday, March 1, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 10, 2021TEAS STATEMENT OF USE RECEIVED
Tuesday, February 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 15, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 15, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 25, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 10, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, May 10, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sunday, November 3, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, April 29, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, April 29, 2019LETTER OF SUSPENSION E-MAILED
Monday, April 29, 2019SUSPENSION LETTER WRITTEN
Monday, April 29, 2019ASSIGNED TO EXAMINER
Sunday, March 10, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, February 20, 2019NEW APPLICATION ENTERED IN TRAM